Skip to main navigation

Investor Relations

  • Who We Are
    • Management
    • Board of Directors
  • Our Focus
    • Dismutase Mimetics
    • Reducing Oral Mucositis
    • Aiming to Increase Efficacy of Radiation Therapy
  • Our Pipeline
    • Avasopasem (GC4419)
    • Rucosopasem (GC4711)
    • Clinical Trials
    • Key Publications
  • Investors
    • IR Home
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Shareholder Services
  • Contact Us

Press Releases

Press Releases
Mar 10, 2023
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
View HTML
PDF Version
Mar 08, 2023
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
View HTML
PDF Version
Feb 15, 2023
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
View HTML
PDF Version
Feb 15, 2023
Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis
View HTML
PDF Version
results

Investor Relations - Horizontal

IR Home
Press Releases
Events and Presentations
Stock Information
Corporate Governance
SEC Filings
Shareholder Services

Tools

Day High:
Day Low:
Volume:
Mar 25, 2023 12:27 AM EDT

Data Provided by Refinitiv.
Minimum 15 minutes delayed.

© Copyright 2023 Galera Therapeutics
Website Design & Development Graphic Beans
Privacy Policy – Terms of Use – Compassionate Use Policy

LinkedIn